Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
复制标题
DOI：
10.1016/s1470-2045(19)30150-0
复制
发表时间：
2019-07-01
期刊：
影响因子：
51.1
通讯作者：
Levis, Mark J.
中科院分区：
文献类型：
--
作者：
Cortes, Jorge E.;Khaled, Samer;Levis, Mark J.
复发性或难治性FLT 3内部串联重复（FLT 3-ITD）阳性急性髓系白血病患者的预后较差，包括复发频率高，对挽救治疗的反应较差，总生存期较FLT 3野生型疾病患者短。我们的目的是评估是否单药quizartinib，口服，高效和选择性的II型FLT 3抑制剂，提高总生存率与挽救chemotherapy.Methods量子-R是一个随机，对照，3期试验在152家医院和癌症中心在19个国家。年龄≥ 18岁、ECOG体能状态评分为0-2且复发性或难治性（首次复合完全缓解持续时间）的合格患者
Background Patients with relapsed or refractory FLT3 internal tandem duplication (FLT3-ITD)-positive acute myeloid leukaemia have a poor prognosis, including high frequency of relapse, poorer response to salvage therapy, and shorter overall survival than those with FLT3 wild-type disease. We aimed to assess whether single-agent quizartinib, an oral, highly potent and selective type II FLT3 inhibitor, improves overall survival versus salvage chemotherapy.Methods QuANTUM-R is a randomised, controlled, phase 3 trial done at 152 hospitals and cancer centres in 19 countries. Eligible patients aged 18 years or older with ECOG performance status 0-2 with relapsed or refractory (duration of first composite complete remission